“Prior research in kidney cancer suggests a paradigm in which HIF-1α plays an anti-tumor role, whereas HIF-2α plays a pro-tumor role, but this was determined primarily using cell lines and animal models,” said Mei Koh, PhD, an HCI investigator and assistant professor in the Department of Pharmacology and Toxicology at the U of U. The current study tested tissue obtained from human patients.
Researchers gathered tissue from more than 380 patients to analyze the relationship between levels of HIF proteins, tumor grade, stage, and patient outcome. These findings were validated using tissue samples from 72 additional patients.
Findings showed that HIF-1α was associated with more aggressive, or high-grade, tumors. The protein was also linked to tumors that spread to other regions in the body (metastasized), as well as to decreased patient survival and increased resistance to therapy. Conversely, HIF-2α was associated with less aggressive, or low-grade, tumors, lack of metastasis, and longer life.
“The entire team was surprised that our findings were almost exactly opposite to what we had expected,” Koh said. “Our view of the HIFs in kidney cancer may need to be revised. We found that HIF-1α, the presumed tumor suppressor, was an indicator of poor patient outcome. HIF-2α, the presumed tumor driver, was significantly associated with better patient outcome. Of note, HIF-1α was detected mainly in tumor-associated macrophages, which are immune cells of the patient, but not within the cells of the tumor. This suggests that these immune cells could play an important role in tumor progression. HIF-2α was detected exclusively within tumor cells.”
A multidisciplinary group of researchers from HCI and other institutions conducted this study. “Diversity in collaborators helped reduce bias, whether conscious or unconscious, in data acquisition and interpretation. It also increased the number of well-annotated tissue samples available to us,” Koh said. Koh also acknowledged the critical work of Sophie Cowman, postdoctoral research associate in the Department of Pharmacology and Toxicology at the U of U. Cowman was first author for this study.
The study was supported by the National Institutes of Health/National Cancer Institute including P30 CA042014 and the Huntsman Cancer Foundation.
Huntsman Cancer Institute (HCI) at the University of Utah is the official cancer center of Utah. The cancer campus includes a state-of-the-art cancer specialty hospital as well as two buildings dedicated to cancer research. HCI treats patients with all forms of cancer and is recognized among the best cancer hospitals in the country by U.S. News and World Report. As the only National Cancer Institute (NCI)-Designated Comprehensive Cancer Center in the Mountain West, HCI serves the largest geographic region in the country, drawing patients from Utah, Nevada, Idaho, Wyoming, and Montana. More genes for inherited cancers have been discovered at HCI than at any other cancer center in the world, including genes responsible for hereditary breast, ovarian, colon, head, and neck cancers, along with melanoma. HCI manages the Utah Population Database, the largest genetic database in the world, with information on more than 11 million people linked to genealogies, health records, and vital statistics. HCI was founded by Jon M. and Karen Huntsman.